20.10.2006 – 08:33

Marseille-Kliniken AG

euro adhoc: Marseille-Kliniken AG
Financial Figures/Balance Sheet
- Turnover extended by 4.4% to 210.4 million Euro in financial year 2005/2006 - Company annual surplus increases by 3.4 million Euro to 9.7 million Euro - Capital ratio rises clearly

  Disclosure announcement transmitted by euro adhoc. The issuer is responsible
  for the content of this announcement.

20.10.2006

Berlin, 20th October 2006. The Marseille-Kliniken AG, (Prime
Standard, ISIN DE 0007783003, MKA) is continuing to grow and is
recording above-average results. In the financial year of 2005/06 the
company’s turnover increased to 210.4 million Euro (previous year:
201.5 million Euro). The EBIT result according to IFRS improved from
23.1 million Euro in the previous year to 25.8 million Euro in the
year under review. The company’s annual surplus improved from 6.3
million Euro to 9.7 million Euro. The DVFA/SG (IFRS) adjusted result
was 9.3 million Euro in the financial year compared to 8.9 million
Euro the previous year. Per share this is equal to a result increase
of 0.03 Euro to 0.76 Euro (previous year: 0.73 Euro). The equity
capital recorded on the balance sheet is 66.8 million Euro as against
62.6 million Euro in the previous year, which equates to a capital
ratio of 20.7% (previous year 15.5%).

The care sector is still the growth driver for turnover and results,
in which the bed capacity was expanded by 1233 beds to 7134 beds
during the financial year (previous year: 5901 beds). Within the
company the entire capacity therefore increased to 8703 beds. With a
turnover of 162.7 million Euro, the Marseille-Kliniken AG achieved a
growth of 11.7 million Euro in the care sector, compared to 151.0
million Euro in the previous year. At 12.9 million Euro the result
according to DVFA/SG (IFRS) exceeded the previous year’s value of
12.5 million Euro  by 0.4 million Euro. The occupancy rate was also
improved, despite the current negative start-up effects from the new
facilities and with 91.6% exceeded the previous year’s figure of
90.7%. Therefore in total the company occupancy rate with 88.2% was
above the level of the previous year of 87.5%.

The rehabilitation sector has been further improved. Through the
closure of two facilities and the purchase of a gerontological
specialist clinic in Büren, the total number of facilities decreased
to 10 (previous year: 11). Therefore, according to plan the bed
capacity in this sector decreased by 103 beds to 1569 beds (previous
year: 1672 beds). The occupancy rate for the entire year was
primarily influenced by the unexpectedly poor third quarter and the
doctor’s strike and decreased from 76.6% in the previous year to
74.2% over the entire year. In the rehabilitation sector the turnover
has been reduced from 50.5 million Euro in the previous year to 47.7
million Euro in the year under review. With -3.6 million Euro the
DVFA/SG adjusted result (IFRS) remained at the level of the previous
year. The restructuring measures in this sector are consistently
being taken and form the basis for a lasting turnaround, so that the
board of directors is counting on positive effects in this sector in
the short to medium term.

End of the ad hoc release

end of announcement                               euro adhoc 20.10.2006 07:55:22

Further inquiry note:

If you have any questions please contact:

Marseille-Kliniken AG Hillermann Consulting
Axel Hölzer Christian Hillermann
CEO Investor Relations
Alte Jakobstraße 79/80 Eppendorfer Baum 5
10709 Berlin 20249 Hamburg
Tel.: 030 / 246 32-400 Tel.: 040 / 414 069-13
Fax: 030 / 246 32-401 Fax: 040 / 414 069-14

Branche: Pharmaceuticals
ISIN: DE0007783003
WKN: 778300
Index: CDAX, Classic All Share, Prime All Share
Börsen: Frankfurter Wertpapierbörse / official dealing/prime standard
Börse Berlin-Bremen / free trade
Baden-Württembergische Wertpapierbörse / free trade
Börse Düsseldorf / free trade
Hamburger Wertpapierbörse / official dealing